WO2001015676A3 - Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides - Google Patents

Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides Download PDF

Info

Publication number
WO2001015676A3
WO2001015676A3 PCT/IB2000/001492 IB0001492W WO0115676A3 WO 2001015676 A3 WO2001015676 A3 WO 2001015676A3 IB 0001492 W IB0001492 W IB 0001492W WO 0115676 A3 WO0115676 A3 WO 0115676A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
hdl cholesterol
triglyceride levels
modulating hdl
Prior art date
Application number
PCT/IB2000/001492
Other languages
English (en)
Other versions
WO2001015676A2 (fr
WO2001015676A9 (fr
Inventor
Michael R Hayden
Angela R Brooks-Wilson
Simon N Pimstone
Susanne M Clee
Original Assignee
Univ British Columbia
Xenon Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/526,193 external-priority patent/US6617122B1/en
Application filed by Univ British Columbia, Xenon Genetics Inc filed Critical Univ British Columbia
Priority to EP00974705A priority Critical patent/EP1239848A2/fr
Priority to JP2001519890A priority patent/JP2003520780A/ja
Priority to AU12919/01A priority patent/AU1291901A/en
Priority to CA002382562A priority patent/CA2382562A1/fr
Publication of WO2001015676A2 publication Critical patent/WO2001015676A2/fr
Publication of WO2001015676A3 publication Critical patent/WO2001015676A3/fr
Publication of WO2001015676A9 publication Critical patent/WO2001015676A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes permettant de traiter des patients ayant un faible taux de HDL cholestérol, un taux de triglycérides supérieur à la normale ou une maladie cardio-vasculaire, en leur administrant des composés qui modulent l'expression ou l'activité de ABC1.
PCT/IB2000/001492 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides WO2001015676A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00974705A EP1239848A2 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
JP2001519890A JP2003520780A (ja) 1999-09-01 2000-09-01 Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
AU12919/01A AU1291901A (en) 1999-09-01 2000-09-01 Compositions and methods for modulating hdl cholesterol and triglyceride levels
CA002382562A CA2382562A1 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15197799P 1999-09-01 1999-09-01
US60/151,977 1999-09-01
US09/526,193 2000-03-15
US09/526,193 US6617122B1 (en) 1999-03-15 2000-03-15 Process for identifying modulators of ABC1 activity
US21395800P 2000-06-23 2000-06-23
US60/213,958 2000-06-23

Publications (3)

Publication Number Publication Date
WO2001015676A2 WO2001015676A2 (fr) 2001-03-08
WO2001015676A3 true WO2001015676A3 (fr) 2002-07-25
WO2001015676A9 WO2001015676A9 (fr) 2003-06-19

Family

ID=27387196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001492 WO2001015676A2 (fr) 1999-09-01 2000-09-01 Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides

Country Status (5)

Country Link
EP (1) EP1239848A2 (fr)
JP (1) JP2003520780A (fr)
AU (1) AU1291901A (fr)
CA (1) CA2382562A1 (fr)
WO (1) WO2001015676A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
JP2003531613A (ja) * 2000-05-02 2003-10-28 アバンテイス・フアルマ・エス・アー Ａｂｃ１遺伝子の調節核酸配列
US20020048572A1 (en) * 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
GB0019290D0 (en) * 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
WO2002012342A2 (fr) * 2000-08-04 2002-02-14 Genaissance Pharmaceuticals, Inc. Haplotypes du gene edg4
US6821750B2 (en) * 2000-11-20 2004-11-23 Tularik Inc. ABCG8 vectors, host cells, and method of making
CA2448484A1 (fr) * 2001-05-25 2002-12-05 Xenon Genetics, Inc. Procedes de diagnostic de maladies cardio-vasculaires, faibles niveaux de cholesterol ldl, et niveaux eleves de triglyceride
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
CA2469435A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
EP1556057A4 (fr) 2002-08-29 2009-07-15 Univ California Agents et procedes pour stimuler la formation osseuse
EP1572660B1 (fr) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Dérives d'isoquinolinone et leur utilisation comme agents thérapeutiques
WO2004058990A2 (fr) * 2002-12-20 2004-07-15 Applera Corporation Polymorphismes genetiques associes a la stenose, procedes de detection, et utilisations
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
WO2006047022A1 (fr) 2004-10-25 2006-05-04 Virginia Commonwealth University Oxysterol sulfate nucleaire, regulateur homeostatique du cholesterol agissant puissamment dans le traitement de l'hypercholesterolemie, de l'hyperlipidemie et de l'atherosclerose
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
JP5227803B2 (ja) 2006-11-24 2013-07-03 ハイクス ラボラトリーズ合同会社 スピロキノン化合物及び医薬組成物
AU2007339325A1 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of PPAR gamma expression by specific osteogenic oxysterols
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
EP2146724A2 (fr) * 2007-03-16 2010-01-27 The Regent of the University of California Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
US8317674B2 (en) 2008-06-11 2012-11-27 Bracco Diagnostics Inc. Shielding assemblies for infusion systems
EP2328635B1 (fr) 2008-06-11 2019-10-16 Bracco Diagnostics Inc. Configurations de structure en coffret pour systèmes de perfusion
NZ605754A (en) * 2010-09-07 2014-06-27 Delaval Holding Ab A cabinet in a milking parlour
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EP2847206A4 (fr) 2012-05-07 2016-01-20 Univ California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
JP2016517888A (ja) 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
EP4101861A1 (fr) 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprenant du 5-cholestène-3, 25-diol,3-sulfate (25 h3s) ou un sel pharmaceutiquement acceptable de celui-ci et au moins un oligosaccharide cyclique
US11752254B2 (en) 2016-09-20 2023-09-12 Bracco Diagnostics Inc. Radioisotope delivery system with multiple detectors to detect gamma and beta emissions
CA3094463A1 (fr) 2018-03-28 2019-10-03 Bracco Diagnostics Inc. Detection precoce de la duree de vie d'un generateur de radio-isotopes

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152152A (en) * 1962-06-21 1964-10-06 Upjohn Co 24-dehydro cholesterol analogs and the process for the preparation thereof
WO1997012853A1 (fr) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Modulateurs rxr selectifs pour les dimeres et leurs methodes d'utilisation
WO1997042215A1 (fr) * 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Procede de preparation de 27-hydroxy cholesterol et de derives apparentes
WO1998057647A1 (fr) * 1997-06-18 1998-12-23 Baylor College Of Medicine Recepteur nucleaire orphelin, coup-tfii, necessaire a l'angiogenese
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000055318A2 (fr) * 1999-03-15 2000-09-21 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
WO2000078971A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1
WO2001003705A1 (fr) * 1999-07-08 2001-01-18 Tularik Inc. Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
WO2001032184A2 (fr) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Gene de transport de cholesterol
WO2001041704A2 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
WO2001066098A2 (fr) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Utilisations therapeutiques des mediateurs ppar
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152152A (en) * 1962-06-21 1964-10-06 Upjohn Co 24-dehydro cholesterol analogs and the process for the preparation thereof
WO1997012853A1 (fr) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Modulateurs rxr selectifs pour les dimeres et leurs methodes d'utilisation
WO1997042215A1 (fr) * 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Procede de preparation de 27-hydroxy cholesterol et de derives apparentes
WO1998057647A1 (fr) * 1997-06-18 1998-12-23 Baylor College Of Medicine Recepteur nucleaire orphelin, coup-tfii, necessaire a l'angiogenese
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
WO2000054759A2 (fr) * 1999-03-15 2000-09-21 Tularik Inc. Modulateurs du lxr
WO2000055318A2 (fr) * 1999-03-15 2000-09-21 University Of British Columbia Methodes et reactifs permettant de moduler les taux de cholesterol
WO2000078971A2 (fr) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1
WO2001003705A1 (fr) * 1999-07-08 2001-01-18 Tularik Inc. Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
WO2001032184A2 (fr) * 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Gene de transport de cholesterol
WO2001041704A2 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
WO2001066098A2 (fr) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Utilisations therapeutiques des mediateurs ppar
WO2001083746A2 (fr) * 2000-05-02 2001-11-08 Aventis Pharma S.A. Acide nucleique regulateur pour le gene abc1, molecule modifiant son activite et applications therapeutiques

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ACCAD M ET AL: "CHOLESTEROL HOMEOSTASIS: A ROLE FOR OXYSTEROLS", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 8, no. 17, 27 August 1998 (1998-08-27), pages R601 - R604, XP001015383, ISSN: 0960-9822 *
COSTET P ET AL: "STEROL-DEPENDENT TRANSACTIVATION OF THE ABC1 PROMOTER BY THE LIVER X RECEPTOR/RETINOID X RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 36, 8 September 2000 (2000-09-08), pages 28240 - 28245, XP000972366, ISSN: 0021-9258 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 1999 (1999-01-01), BRENDEL CAROLE ET AL: "Transcriptional regulation of cholesterol metabolism.", XP002176374, Database accession no. PREV199900152920 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TABATA, TOSHIKAZU ET AL: "Hypocholesterolemic activity of phytosterol. II", XP002175493, retrieved from STN Database accession no. 93:160958 *
JANOWSKI ET AL: "An oxysterol signalling pathway mediated by the nuclear receptor LXR.alpha", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 383, no. 6602, 24 October 1996 (1996-10-24), pages 728 - 731, XP002104644, ISSN: 0028-0836 *
JANOWSKI ET AL: "Structural requirements of ligands for the oxysterol liver X receptors LXR.alpha. and LXR.beta", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 1, 5 January 1999 (1999-01-05), pages 266 - 271, XP002104645, ISSN: 0027-8424 *
KRUT L H: "CLEARANCE OF SUB CUTANEOUS IMPLANTS OF CHOLESTEROL IN THE RAT PROMOTED BY OXIDATION PRODUCTS OF CHOLESTEROL A POSTULATED ROLE FOR OXY STEROLS IN PREVENTING ATHERO SCLEROSIS", ATHEROSCLEROSIS, vol. 43, no. 1, 1982, pages 105 - 118, XP001016481, ISSN: 0021-9150 *
LANGMANN T ET AL: "MOLECULAR CLONING OF THE HUMAN ATP-BINDING CASSETTE TRANSPORTER 1 (HABC1): EVIDENCE FOR STEROL-DEPENDENT REGULATION IN MACROPHAGES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 257, no. 1, 2 April 1999 (1999-04-02), pages 29 - 33, XP000877240, ISSN: 0006-291X *
LAWN R M ET AL: "THE TANGIER DISEASE GENE PRODUCT ABC1 CONTROLS THE CELLULAR APOLIPOPROTEIN-MEDIATED LIPID REMOVAL PATHWAY", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 104, no. 8, October 1999 (1999-10-01), pages R25 - R31, XP000884782, ISSN: 0021-9738 *
LEHMANN JUERGEN M ET AL: "Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 6, 1997, pages 3137 - 3140, XP001015265, ISSN: 0021-9258 *
M-S (MEDECINE SCIENCES), vol. 15, no. 1, January 1999 (1999-01-01), pages 56 - 62, XP001016141, ISSN: 0767-0974 *
RUST S ET AL: "TANGIER DISEASE IS CAUSED BY MUTATIONS IN THE GENE ENCODING ATP--BINDING CASSETTE TRANSPORTER 1", NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08-01), pages 352 - 355, XP000884993, ISSN: 1061-4036 *
SANTAMARINA-FOJO S ET AL: "COMPLETE GENOMIC SEQUENCE OF THE HUMAN ABCA1 GENE: ANALYSIS OF THE HUMAN AND MOUSE ATP-BINDING CASSETTE A PROMOTER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 14, 5 July 2000 (2000-07-05), pages 7987 - 7992, XP000946151, ISSN: 0027-8424 *
SCHROEPFER, GEORGE J., JR.: "Design of new oxysterols for regulation of cholesterol metabolism", CURR. PHARM. DES. (1996), 2(1), 103-120, XP001014779 *
SCHWARTZ K ET AL: "ABC1 GENE EXPRESSION AND APOA-I-MEDIATED CHOLESTER0L EFFLUX ARE REGULATED BY LXR", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 274, no. 3, 11 August 2000 (2000-08-11), pages 794 - 802, XP000960872, ISSN: 0006-291X *
YAKUGAKU ZASSHI (1980), 100(5), 546-52 *

Also Published As

Publication number Publication date
WO2001015676A2 (fr) 2001-03-08
WO2001015676A9 (fr) 2003-06-19
EP1239848A2 (fr) 2002-09-18
AU1291901A (en) 2001-03-26
JP2003520780A (ja) 2003-07-08
CA2382562A1 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001015676A3 (fr) Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
WO2003068170A3 (fr) Traitement de denrees alimentaires aux enzymes contre l'enteropathie au gluten
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
NO20002172L (no) FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
WO2003051313A3 (fr) Prevention et traitement des troubles lies au stress oxydatif a l'aide de glutathione et d'enzymes de detoxification de phase ii
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
WO1998046588A3 (fr) Composes et therapies destines a la prevention d'affections vasculaires ou non vasculaires
WO2001005388A3 (fr) Composition destinee au traitement des troubles de la secretion externe
WO2002060389A3 (fr) Procede permettant de traiter l'insuffisance cardiaque chronique et/ou des taux de cholesterol eleves par l'acide 3,5-diiodothyropropionique et procede de preparation de ce dernier
EP1283058A4 (fr) Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
WO2005096704A3 (fr) Composition hypocholesterolemiante
WO1999004772A3 (fr) Levobupivacine et son utilisation
CA2350992A1 (fr) Moyens de prevention ou therapeutique contre la myocardite, la cardiomyopathie dilatee et l'insuffisance cardiaque contenant des inhibiteurs nf-kb en tant qu'ingredient actif
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l'incontinence urinaire
CA2253130A1 (fr) Medicament pour traiter l'obesite et ameliorer le metabolisme lipidique
CA2300405A1 (fr) Utilisation d'inhibiteurs de cholinesterase dans le traitement des troubles deficitaires de l'attention
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
WO2001026651A3 (fr) Modulateurs selectifs des recepteurs oestrogeniques pour traiter l'hypertension, des maladies cardio-vasculaires et la resistance a l'insuline ou reduire le risque de contracter ces maladies
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2382562

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 519890

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000974705

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12919/01

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000974705

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 46 AND 48, DESCRIPTION, REPLACED BY NEW PAGES 46 AND 48; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

WWW Wipo information: withdrawn in national office

Ref document number: 2000974705

Country of ref document: EP